Clinical advances of 18F-FDG PET/CT in evaluating differentiation of recurrent or metastatic differentiated thyroid cancer and guiding 131I therapy
10.3760/cma.j.cn321828-20210413-00110
- VernacularTitle:18F-FDG PET/CT评估分化型甲状腺癌复发或转移灶分化程度及其指导 131I治疗的应用价值
- Author:
Yongji JIANG
1
;
Yanlei HUO
;
Zhongwei LYU
;
Chao MA
Author Information
1. 同济大学附属第十人民医院核医学科，上海 200072
- Keywords:
Thyroid neoplasms;
Radiotherapy;
Iodine radioisotopes;
Positron-emission tomography;
Tomography, X-ray computed;
Fluorodeoxyglucose F18;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2022;42(9):559-562
- CountryChina
- Language:Chinese
-
Abstract:
Differentiated thyroid cancer (DTC) is prone to relapse and metastasize. In addition to thyroglobulin (Tg) and its antibodies, ultrasound and 131I whole-body scan (WBS), 18F-FDG PET/CT gains more use in the setting of recurrent or metastatic DTC and shows promise. This article mainly reviews the value of 18F-FDG PET/CT in the location of recurrent or metastasized DTC with negative 131I WBS but positive Tg ( 131I WBS-/Tg+ ), evaluating their differentiation, predicting the prognosis, guiding 131I treatment and its value in restaging DTC with moderate and high risk of relapse and guiding treatment decision.
